Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis

被引：20

作者：

Anpalakhan, Shobana ^{[1
]}

Signori, Alessio ^{[2
]}

Cortellini, Alessio ^{[3
,4
]}

Verzoni, Elena ^{[5
]}

Giusti, Raffaele ^{[6
]}

Aprile, Giuseppe ^{[7
]}

Ermacora, Paola ^{[8
]}

Catino, Annamaria ^{[9
]}

Pipitone, Stefania ^{[10
]}

Di Napoli, Marilena ^{[11
]}

Scotti, Vieri ^{[12
]}

Mazzoni, Francesca ^{[13
]}

Guglielmini, Pamela F. ^{[14
]}

Veccia, Antonello ^{[15
]}

Maruzzo, Marco ^{[16
]}

Schinzari, Giovanni ^{[17
]}

Casadei, Chiara ^{[18
]}

Grossi, Francesco ^{[19
]}

Rizzo, Mimma ^{[20
,21
]}

Montesarchio, Vincenzo ^{[22
]}

Verderame, Francesco ^{[23
]}

Mencoboni, Manlio ^{[24
]}

Zustovich, Fable ^{[25
]}

Fratino, Lucia ^{[26
]}

Accettura, Caterina ^{[27
]}

Cinieri, Saverio ^{[28
,29
]}

Tondini, Carlo Alberto ^{[30
]}

Camerini, Andrea ^{[31
]}

Banzi, Maria Chiara ^{[32
]}

Soraru, Mariella ^{[33
]}

Zucali, Paolo Andrea ^{[34
,35
]}

Vignani, Francesca ^{[36
,37
]}

Ricciardi, Serena ^{[38
]}

Russo, Antonio ^{[39
]}

Cosenza, Agnese ^{[40
]}

Di Maio, Massimo ^{[36
,37
]}

De Giorgi, Ugo ^{[18
]}

Pignata, Sandro ^{[11
]}

Giannarelli, Diana ^{[41
]}

Pinto, Carmine ^{[32
]}

Buti, Sebastiano ^{[40
,42
,43
]}

Fornarini, Giuseppe ^{[44
]}

Rebuzzi, Sara Elena ^{[45
,46
]}

Rescigno, Pasquale ^{[47
]}

Addeo, Alfredo ^{[48
]}

Banna, Giuseppe L. ^{[1
,49
]}

Bersanelli, Melissa ^{[40
,50
]}

机构：

[1] Portsmouth Hosp Univ NHS Trust, Portsmouth, Hants, England

[2] Univ Genoa, Genoa, Italy

[3] Fdn Policlin Univ Campus Biomed, Operat Res Unit Med Oncol, Rome, Italy

[4] Imperial Coll London, Hammersmith Hosp Campus, Dept Surg & Canc, London, England

[5] Fdn IRCCS Ist Nazl Tumori, SS Oncol Genitourinaria, Milan, Italy

[6] Azienda Osped Univ St Andrea, Med Oncol Unit, Rome, Italy

[7] San Bortolo Gen Hosp, ULSS, Dept Oncol, 8 Berica East Dist, Vicenza, Italy

[8] Azienda Sanit Univ Integrata Friuli Cent, Presidio Osped Univ Santa Maria Misericordia, Dept Oncol, Udine, Italy

[9] IRCCS Ist Tumori Giovanni Paolo II, Med Thorac Oncol Unit, Bari, Italy

[10] Univ Hosp Modena, Med Oncol Unit, Modena, Italy

[11] Univ Modena & Reggio Emilia, Azienda Osped Univ Modena, Dept Hematol & Oncol, Modena, Italy

[12] Azienda Osped Univ Careggi, Radiat Oncol Unit, Dept Oncol, Florence, Italy

[13] Careggi Univ Hosp, Dept Oncol, Med Oncol Unit, Florence, Italy

[14] AO SS Antonio & Biagio & C Arrigo, SC Oncol, Alessandria, Italy

[15] Santa Chiara Hosp, Med Oncol, Trento, Italy

[16] Ist Oncol Veneto IOV IRCCS, Oncol Med 1, Padua, Italy

[17] Fdn Policlin Univ A Gemelli IRCCS, Med Oncol, Rome, Italy

[18] IRCCS, Dept Med Oncol, IRST Dino Amadori, Meldola, Italy

[19] Univ Insubria, ASST Sette Laghi, Med Oncol Div, Varese, Italy

[20] IRCCS Ist Clin Sci Maugeri, Div Translat Oncol, Pavia, Italy

[21] Azienda Ospesaliera Univ Consorziale, Med Oncol Unit, Policlin Bari, Bari, Italy

[22] Osped Monaldi, Azienda Osped Specialist Colli, UOC Oncol, Naples, Italy

[23] Osped Riuniti Villa Sofia Cervello, AO Azienda Osped, Oncol Unit, Palermo, Italy

[24] Osped Villa Scassi, Oncol Med, Genoa, Italy

[25] Osped San Martino Genova, UOC Oncol Belluno, Dipartimento Oncol Clin, AULSS 1 Dolomiti, Belluno, Italy

[26] Ctr Riferimento Oncol Aviano CRO IRCCS, Med Oncol Unit, Aviano, Pordenone, Italy

[27] Osped Vito Fazzi, Med Oncol Unit, Lecce, Italy

[28] Senatore Antonio Perrino Hosp, ASL Brindisi, Med Oncol Div, Brindisi, Italy

[29] Senatore Antonio Perrino Hosp, Breast Unit, ASL Brindisi, Brindisi, Italy

[30] Osped Papa Giovanni XXIII, Med Oncol, Bergamo, Italy

[31] Osped Versilia, Oncol Med, Lido Di Camaiore, Italy

[32] AUSL IRCCS Reggio Emilia, Med Oncol, Comprehens Canc Ctr, Reggio Emilia, Italy

[33] Camposampiero Hosp, Med Oncol, Padua, Italy

[34] Humanitas Univ, Dept Biomed Sci, Milan, Italy

[35] IRCCS Humanitas Res Hosp, Dept Oncol, Milan, Italy

[36] Univ Turin, Dept Oncol, Turin, Italy

[37] AO Ordine Mauriziano, Med Oncol, Turin, Italy

[38] San Camillo Forlanini Hosp, Pulm Oncol Unit, Rome, Italy

[39] Univ Palermo, Dipartimento Discipline Chirurg Oncol & Stomatol, Palermo, Italy

[40] Univ Hosp Parma, Med Oncol Unit, Parma, Italy

[41] Fdn Policlin Univ A Gemelli IRCCS, Facil Epidemiol & Biostat, Rome, Italy

[42] Univ Parma, Dept Med & Surg, Parma, Italy

[43] Univ Parma, Med & Surg Dept, Parma, Italy

[44] IRCCS Osped Policlin San Martino, Med Oncol Unit 1, Genoa, Italy

[45] Osped San Paolo, Med Oncol Unit, I-17100 Savona, Italy

[46] Univ Genoa, Dept Internal Med & Med Specialties DiMI, Genoa, Italy

[47] Newcastle Univ, Ctr Canc, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England

[48] Univ Hosp Geneva, Geneva, Switzerland

[49] Univ Portsmouth, Fac Sci & Hlth, Sch Pharm & Biomed Sci, Portsmouth, Hants, England

[50] FICOG, Milan, Italy

来源：

ISCIENCE | 2023年 / 26卷 / 11期

关键词：

TO-LYMPHOCYTE RATIO; NEUTROPHIL; SURVIVAL; CANCER; INDEX; CARCINOMA;

D O I：

10.1016/j.isci.2023.107970

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammatory index (SII) have been re-ported as prognosticators in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and mela-noma. This analysis of the INVIDIa-2 study on influenza vaccination in patients with cancer treated with immune checkpoint inhibitors (ICIs) assessed NLR and SII on overall survival (OS) by literature-reported (LR), receiver operating characteristic curve (ROC)-derived (ROC) cutoffs or as continuous variable (CV). NLR and SII with ROC cutoffs of <3.4 (p < 0.001) and <831 (p < 0.001) were independent factors for OS in multivariate analysis. SII with LR, ROC, or CV significantly predicted OS in NSCLC (p = 0.002, p = 0.003, p = 0.003), RCC (p = 0.034, p = 0.014, p = 0.014), and melanoma (p = 0.038, p = 0.022, p = 0.019). NLR with LR and ROC cutoffs predicted OS in first line (p < 0.001 for both) and second line or beyond (p = 0.006 for both); likewise SII (p < 0.001; p = 0.002 and p < 0.001). NLR and SII are prognosti-cators in NSCLC, RCC, and melanoma treated with ICIs.

引用

页数：14

共 43 条

[21] Prognostic and Clinicopathological Significance of the Systemic Immune-Inflammation Index in Patients With Renal Cell Carcinoma: A Meta-Analysis [J].

Jin, Mingyu ;

Yuan, Shaoying ;

Yuan, Yiming ;

Yi, Luqi .

FRONTIERS IN ONCOLOGY, 2021, 11

[22] Neutrophil to lymphocyte ratio is an independent predictor of outcome for patients undergoing definitive resection for stage IV melanoma [J].

Kanatsios, Stefanos ;

Project, Melbourne Melanoma ;

Suen, Connie S. N. Li Wai ;

Cebon, Jonathan Simon ;

Gyorki, David E. .

JOURNAL OF SURGICAL ONCOLOGY, 2018, 118 (06) :915-921

[23] A conceptual framework for prognostic research [J].

Kent, Peter ;

Cancelliere, Carol ;

Boyle, Eleanor ;

Cassidy, J. David ;

Kongsted, Alice .

BMC MEDICAL RESEARCH METHODOLOGY, 2020, 20 (01)

[24] Direct Signaling between Platelets and Cancer Cells Induces an Epithelial-Mesenchymal-Like Transition and Promotes Metastasis [J].

Labelle, Myriam ;

Begum, Shahinoor ;

Hynes, Richard O. .

CANCER CELL, 2011, 20 (05) :576-590

[25] Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab [J].

Liu, Jingjing ;

Li, Shuang ;

Zhang, Shuang ;

Liu, Ying ;

Ma, Lixia ;

Zhu, Jing ;

Xin, Ying ;

Wang, Ying ;

Yang, Changliang ;

Cheng, Ying .

JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2019, 33 (08)

[26] REporting recommendations for tumour MARKer prognostic studies (REMARK) [J].

McShane L.M. ;

Altman D.G. ;

Sauerbrei W. ;

Taube S.E. ;

Gion M. ;

Clark G.M. .

British Journal of Cancer, 2005, 93 (4) :387-391

[27]

Mezquita L., 2017, ANN ONCOL, V28, pV473

[28] Systemic immune signature of inflammation in metastatic melanoma (MM) patients treated with ipilimumab (IPI) and carboplatin/paclitaxel (CP). [J].

Miller, Wilson H. ;

Jamal, Rahima ;

Cocolakis, Eftihia ;

Thebault, Pamela ;

Friedmann, Jennifer Elisabeth ;

Kazemi, Shirin ;

Dionne, Jeanne ;

Cailhier, Jean-Francois ;

Lepage, Stephanie ;

Belanger, Karl ;

Ayoub, Jean-Pierre M. ;

Le, H. B. ;

Lambert, Caroline ;

El Hajjar, Jida ;

Van Kempen, Leon ;

Spatz, Alan ;

Lapointe, Rejean .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)

[29] Systemic immune inflammation index is a promising non-invasive marker for the prognosis of the patients with localized renal cell carcinoma [J].

Ozbek, Emin ;

Besiroglu, Huseyin ;

Ozer, Kutan ;

Horsanali, Mustafa Ozan ;

Gorgel, Sacit Nuri .

INTERNATIONAL UROLOGY AND NEPHROLOGY, 2020, 52 (08) :1455-1463

[30]

Rebordao Pires M., 2022, IMMUNOONCOLOGY TECHN, V16

← 1 2 3 4 5 →